Start Your Free Review
Answer 2-3 quick questions to review your potential case.
Verified against court records, regulatory records, and peer-reviewed research.
Current Settlement Status
As of February 2026, no hair relaxer cases have settled or gone to trial. The MDL is in pre-trial discovery and expert preparation. Daubert hearings on general causation are scheduled for April–June 2026, with bellwether trials expected in mid-2027. Settlement negotiations typically begin in earnest after bellwether outcomes establish value ranges.
Projected Settlement Tiers
Attorney estimates based on comparable mass tort outcomes: Tier 1 (uterine fibroids with hysterectomy): $90,000–$150,000; Tier 2 (uterine/endometrial cancer): $200,000–$750,000; Tier 3 (ovarian cancer or young-adult uterine cancer): $300,000–$1,000,000+. Younger victims and more severe cancer diagnoses command higher values.
Comparable Mass Tort Benchmarks
The talcum powder ovarian cancer litigation ($6.5B for ~60,000 claimants = ~$108K average) and Roundup cancer litigation ($10.9B for ~66,000 claimants = ~$165K average) provide relevant benchmarks. Individual bellwether verdicts in those cases reached much higher amounts.
When to Expect Resolution
Late 2027 at the earliest for global settlement. Filing now is critical — the statute of limitations is running, and being in the MDL pipeline when settlement programs are established ensures your case is included.
Scientific Evidence
Hair Relaxer Use and Risk of Uterine Cancer in the Black Women's Health Study
Bertrand KA, Coogan PF, Palmer JR (2023). Environmental Research
View on PubMed→Use of Straighteners and Other Hair Products and Incident Uterine Cancer
Chang CJ, O'Brien KM, Keil AP, Gaston SA, Jackson CL, Sandler DP, White AJ (2022). Journal of the National Cancer Institute
View on PubMed→Use of Hair Products in Relation to Ovarian Cancer Risk
White AJ, Sandler DP, et al. (2021). Carcinogenesis
View on PubMed→Frequently Asked Questions
What is the hair relaxer litigation about?
Do I qualify for a hair relaxer lawsuit?
Is there a deadline to file a hair relaxer claim?
How much does it cost to pursue a hair relaxer claim?
What kinds of compensation can a hair relaxer claim seek?
Related Pages
Hair Relaxer Uterine Cancer
Uterine cancer is the primary injury in the hair relaxer litigation. The NIH Sister Study found a 155% increased risk (HR 2.55) for frequent users. Approximately 67,000 Americans are diagnosed with uterine cancer annually.
Hair Relaxer Ovarian Cancer
The Sister Study found hair relaxer users face a 2.19x increased risk of ovarian cancer. Ovarian cancer is often called the "silent killer" because symptoms are vague until advanced stages, making early detection difficult.
Hair Relaxer Endometriosis
Chemical hair relaxers contain EDCs linked to endometriosis — a painful condition where uterine-like tissue grows outside the uterus. Phthalates and parabens in relaxers promote endometrial implant growth through estrogen mimicry.
L'Oréal Hair Relaxer Lawsuit
L'Oréal is the primary defendant in the hair relaxer MDL through its subsidiary SoftSheen-Carson, maker of Dark & Lovely and Optimum Care. L'Oréal is the world's largest beauty company with €38+ billion in annual revenue.
Revlon Dark and Lovely Lawsuit
Revlon is a defendant in the hair relaxer MDL despite filing bankruptcy in 2022. Revlon maintains insurance coverage and allocated ~$44 million for hair relaxer claims in its reorganization plan. Products include Creme of Nature and Revlon Realistic.
Hair Relaxer Chemical Exposure
Hair relaxers contain at least 45 endocrine-disrupting chemicals across 10 chemical classes. 84% of these chemicals are NOT listed on product labels. The chemicals enter the body through the scalp, whose protective barrier is compromised by the relaxing process itself.
Hair Relaxer Lawsuit Black Women
Hair relaxer lawsuits disproportionately affect Black women, who were the primary marketing target, comprise 60% of affected users, and face twice the uterine cancer mortality rate of white women. This is both a product liability and a racial justice case.
Hair Relaxer Cancer Lawsuits Lawsuit
Chemical hair relaxers and straighteners contain endocrine-disrupting chemicals (EDCs) — including phthalates, parabens, formaldehyde, and cyclosiloxanes — that mimic estrogen and disrupt the hormonal system. The NIH/NIEHS Sister Study (2022) found that women who frequently used these products faced more than double the risk of uterine cancer. Over 14,700 lawsuits are consolidated in MDL 3060 in the Northern District of Illinois, with bellwether trials expected in 2027. The litigation disproportionately affects Black women, who were the primary marketing target and comprise approximately 60% of affected users.
View full case overview